Ribavirin modulates the conversion of human CD4+ CD25- T cell to CD4+ CD25+ FOXP3+ T cell via suppressing interleukin-10-producing regulatory T cell

Immunology

Volumn 137, Issue 3, 2012, Pages 259-270

  Kobayashi, Tamaki ^a   Nakatsuka, Katsuhisa ^a   Shimizu, Masumi ^a   Tamura, Hideto ^a   Shinya, Eiji ^a   Atsukawa, Masanori ^a   Harimoto, Hirotomo ^a   Takahashi, Hidemi ^a   Sakamoto, Choitsu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Forkhead box P3; Interleukin 10; Regulatory T cell; Regulatory T1 cell; Ribavirin

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; RIBAVIRIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVITY; CELL SURFACE; DOWN REGULATION; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; RIBAVIRIN; T-LYMPHOCYTES, REGULATORY;

EID: 84866856198     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12005     Document Type: Article

References (66)

1. Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009; 21:612-8.
2. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 2007; 19:203-8.
3. + T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002; 35:190-8.
4. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-96.
5. Osna N, Silonova G, Vilgert N et al. Chronic hepatitis C: T-helper1/T-helper2 imbalance could cause virus persistence in peripheral blood. Scand J Clin Lab Invest 1997; 57:703-10.
6. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1449-512.
7. Mills KHG. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841-55.
8. Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-57.
9. Kuchorll VK, Das MP, Brown JA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 1995; 80:707-18.
10. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-87.
11. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212:8-27.
12. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389-400.
13. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3:253-7.
14. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-40.
15. - cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J Immunol 2004; 172:5213-21.
16. + regulatory T cells by continuous antigen stimulation. J Leukoc Biol 2008; 83:1111-7.
17. + regulatory T cells induced by immunosuppressive drugs and inhibited by T helper type 1 (TH1) and TH2-inducing cytokines. J Exp Med 2002; 195:603-16.
18. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology 2005; 117:433-42.
19. + T cell responses. J Exp Med 2003; 198:889-901.
20. + regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004; 78:2454-9.
21. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res 2010; 107:57-117.
22. high regulatory T cells are overpresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173:1444-53.
23. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345-52.
24. + regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40:1062-71.
25. Wu JZ, Lin CC, Hong Z. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother 2003; 52:543-6.
26. McHutchinson JG, Gordon SC, Schiff ER et al. Interferon α2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
27. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79:2381-91.
28. Ning Q, Brown D, Parodo J et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160:3487-93.
29. Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000; 33:791-8.
30. + T-cells and their interleukin-10 secretion to assist clearance of hepatitis C virus. J Gastroenterol Hepatol 2012; 27:823-31.
31. + T reg cells. J Exp Med 2006; 203:1701-11.
32. Tam JY, Pai B, Bard J, Lim C, Averett DR, Pjan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30:376-82.
33. high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-53.
34. Tedder TF, Cooper MD, Clement LT. Human lymphocyte differentiation antigens HB-10 and HB-11. II. Differential production of B cell growth and differentiation factors by distinct helper T cell subpopulations. J Immunol 1985; 134:2989-94.
35. Morimoto C, Letvin NL, Distaso JA, Aldrich WR, Schlossman SF. The isolation and characterization of the human suppressor inducer T cell subset. J Immunol 1985; 134:1508-15.
36. + regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10:849-59.
37. + T cells. Adv Immunol 2010; 105:99-130.
38. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212:28-50.
39. + T cells. J Exp Med 1996; 184:19-29.
40. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J Exp Med 2001; 194:629-44.
41. Sintchak MD, Nimmesqern E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000; 47:163-84.
42. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C subgenomic replicon RNA. Virology 2003; 310:333-42.
43. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445:766-70.
44. Ghany MG, Kleiner DE, Alter H et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124:97-104.
45. Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond.) 2007; 112:141-55.
46. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436:946-52.
47. Kanto T, Hayashi N, Takehara T, Kuzushita N, Ito A, Sasaki Y, Kasahara A, Hori M. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162:5584-91.
48. Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, Cormier M, Szabo G. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-α and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 2006; 177:6758-68.
49. Sugimoto K, Ikeda F, Stadanlick J, Nines FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38:1437-48.
50. + T cell frequency and function during acute hepatitis C presage chronic evolution. Gut 2006; 55:1370-1.
51. + regulatory T-cells in hepatitis C virus infection. J Virol 2008; 82:5043-53.
52. + T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 2006; 107:4424-32.
53. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105:2862-8.
54. + adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006; 177:246-54.
55. Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M, Skaar T, De Petris G. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009; 182:216-24.
56. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579-88.
57. Rong G, Zhou Y, Xiong Y et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 2009; 156:217-25.
58. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2009; 25:215-22.
59. Bos R, van Duikeren S, Morreau H et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008; 68:8446-55.
60. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127:759-67.
61. + T lymphocytes. J Immunol 2009; 183:3720-30.
62. Bonertz A, Weitz J, Pietsch DH et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311-21.
63. Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin JH, Wei L, Chen HS. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. Int J Oncol 2010; 36:841-8.
64. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the Forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007; 67:371-80.
65. Nizar S, Copier J, Meyer B, Bodman-Smith M, Galustian C, Kumar D, Dalgleish A. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009; 100:1697-703.
66. + T-cell responses in patients with advanced HCC. J Immunother 2010; 33:211-8.